Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04613128
Other study ID # PROMISE-OB-18 Pediatric Study
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date June 11, 2021
Est. completion date December 19, 2025

Study information

Verified date December 2023
Source Seattle Children's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective, multi-center observational study. The study is designed to measure the clinical effectiveness of elexacaftor, tezacaftor and ivacaftor (ETI) triple combination therapy in children (6-11 years of old) with one or more copies of the F508del mutation, study the effects of ETI across a number of CF disease manifestations, and collect specimens for future research. Subjects in the study will have one "before ETI" visit within 30 days before initiation of the therapy and five "after ETI" visits over a 24-month follow-up period. Participants who have participated in the original PROMISE Pediatric Sub-Study have the option of participating in a long-term extension with annual visits performed at the 36- and 48-month timepoints. The durability of the clinical and biological changes in the PROMISE Pediatric Sub-Study can be assessed with extended follow-up, which would enable the sub-studies to consider potential clinical consequences of the biological or physiological effects being studied. This work will help to inform long term prognosis and feasibility of certain clinical trials outcomes for interventional studies and may be useful when considering research priorities in drug development. The duration of participation for each subject is 24 months (with an additional 24 months if participants agree to the optional long-term extension). NOTE: FDA has granted approval for elexacaftor, tezacaftor and ivacaftor in the 6-11 age group.


Description:

While nearly 2000 mutations have been described, the most common disease causing CFTR mutation is F508del, which is found in >85% of patients followed in the US CF Patient Registry. Two CFTR corrector drugs (elexacaftor and tezacaftor) plus the potentiator ivacaftor have been developed and approved as a triple combination therapy for CF patients (12 years old and above) with one or two copies of the F508del mutation. We predict that over 90% of pediatric CF patients (age 6-11 y/o) will be eligible for highly effective CFTR modulator therapy in the U.S. The PROMISE Pediatric Study is designed to measure the direct and indirect CFTR dependent anion secretion by collecting and analyzing clinical research outcomes and biomarkers on pediatric patients both before and after they begin treatment with ETI. This study will investigate the impact of ETI across a wide range of CF disease manifestations and organ systems. While specific biomarkers of special interest have been selected for detailed analysis in this study, an additional important goal is to collect blood, urine, stool, and airway epithelial cell specimens for long-term storage in a biorepository to enable future research. These samples can be made available for research beyond the current scope of work. The PROMISE Pediatric Study will provide a coordinated collection of clinical research outcomes data that can be linked with these specimens.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 180
Est. completion date December 19, 2025
Est. primary completion date December 19, 2025
Accepts healthy volunteers No
Gender All
Age group 6 Years to 11 Years
Eligibility Inclusion Criteria: 1. Written parental informed consent and assent obtained from subject and the subject's legal guardian. 2. Be willing and able to adhere to the study visit schedule and other protocol requirements. 3. All genders 6-11 years old on Day 1. 4. Diagnosis of CF. 5. CFTR mutations consistent with the FDA labeled indication for the ETI. 6. Physician intent to prescribe the ETI. 7. Able to attempt the testing and procedures required for this study, as judged by the investigator. 8. Enrolled in the Cystic Fibrosis Foundation Patient Registry. 9. Clinically stable with no significant changes in health status within the 14 days prior to Visit 1 (and inclusive of Visit 1). Exclusion Criteria: 1. Has any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives. 2. Use of any ETI within the 180 days prior to Visit 1. 3. Any acute use of antibiotics (oral, inhaled or IV) or acute use of systemic corticosteroids within the 14 days prior to Visit 1 (inclusive of Visit 1) for lower respiratory tract symptoms. 4. Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline, azithromycin, inhaled tobramycin, Cayston®, Kalydeco, Orkambi®, Symdeko®) within the 4 weeks prior to Visit 1 (inclusive of Visit 1). 5. Use of an investigational agent within the 28 days prior to Visit 1. 6. Use of chronic oral corticosteroids (equivalent to 10 mg. or more per day of prednisone) within the 28 days prior to Visit 1. 7. Treatment for nontuberculous mycobacterial (NTM) infection, consisting of = two antibiotics (oral, IV, and/or inhaled) within the 28 days prior to Visit 1. 8. History of lung or liver transplantation,or listing for organ transplantation.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Children's Hospital Colorado Aurora Colorado
United States John Hopkins University Baltimore Maryland
United States University of Alabama at Birmingham Birmingham Alabama
United States Boston Children's Hospital, Brigham & Women's Hospital Boston Massachusetts
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center Cleveland Ohio
United States Baylor College of Medicine Houston Texas
United States Riley Hospital for Children Indianapolis Indiana
United States University of Iowa Iowa City Iowa
United States Children's Mercy Kansas City Kansas City Missouri
United States University of Wisconsin Madison Wisconsin
United States Children's Hospital of Wisconsin Milwaukee Wisconsin
United States The Minnesota Cystic Fibrosis Center Minneapolis Minnesota
United States Stanford University Medical Center Palo Alto California
United States Oregon Health Sciences University Portland Oregon
United States Virginia Commonwealth University Richmond Virginia
United States Washington University School of Medicine Saint Louis Missouri
United States Seattle Children's Hospital Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Nicole Hamblett Cystic Fibrosis Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sweat Chloride at 6 months Change in sweat chloride from Baseline to 6 months. 6 months
Primary Sweat Chloride at 24 months Change sweat chloride from Baseline to 24 months. 24 months
Primary Forced expiratory volume at one second (FEV1) at 6 months Change in FEV1 from Baseline to 6 months. 6 months
Primary Forced expiratory volume at one second (FEV1) at 24 months Change in FEV1 from Baseline to 24 months. 24 months
Primary Lung Clearance Index (LCI) at 6 months Change Lung Clearance Index (LCI) from baseline to 6 months. 6 months
Primary Lung Clearance Index (LCI) at 24 months Change Lung Clearance Index (LCI) from baseline to 24 months. 24 months
Secondary Weight at 6 Months Change in weight from Baseline to 6 months. 6 months
Secondary Weight at 24 Months Change in weight from Baseline to 24 months. 24 months
Secondary BMI at 6 Months Change in BMI from Baseline to 6 months. 6 months
Secondary BMI at 24 Months Change in BMI from Baseline to 24 months. 24 months
Secondary Cystic Fibrosis Questionnaire Revised (CFQ-R) at 6 Months Change in CFQ-R (respiratory domain) from Baseline to 6 months. 6 months
Secondary Cystic Fibrosis Questionnaire Revised (CFQ-R) at 24 Months Change in CFQ-R (respiratory domain) from Baseline to 24 months. 24 months
See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A